Tags

Type your tag names separated by a space and hit enter

An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
Dig Dis Sci 2016; 61(1):99-106DD

Abstract

BACKGROUND

Osteopenia and osteoporosis are considered to be extra-intestinal manifestations of inflammatory bowel disease (IBD). Anti-tumor necrosis factor (TNF)-α biologics have been introduced as novel medications for an active IBD. However, it is still not well documented whether anti-TNF-α affects the frequency of bone loss or abnormality of bone mineral markers among patients with IBD.

AIMS

This study was to investigate the biochemical basis of low bone mineral density (BMD) and increased turnover in IBD during infliximab (IFX) therapy.

METHODS

Forty patients with Crohn's disease (CD), 80 patients with ulcerative colitis (UC), and 65 age- and gender-matched controls were included. BMD was measured with dual-energy X-ray absorptiometry, and vitamins K and D were measured as serum undercarboxylated osteocalcin (ucOC) and 1,25-(OH)2D, respectively. Bone formation and resorption were based on measuring bone-specific alkaline phosphatase (BAP) and serum N-terminal telopeptide of type I collagen (NTx), respectively.

RESULTS

Significantly lower BMD was found in patients with UC and CD as compared to controls (P < 0.05). BAP, 1,25-(OH)2D, ucOC, and NTx were significantly higher in CD patients, but not in UC patients as compared to controls (P < 0.05). Further, serum NTx level was significantly higher in CD patients who were receiving IFX as compared to CD patients who were not receiving IFX (P < 0.01).

CONCLUSIONS

A lower BMD and higher bone metabolism markers were found in CD patients as compared to controls or UC patients. A significant increased serum level of NTx, a biochemical marker of increased bone resorption, was observed in CD patients during IFX therapy.

Authors+Show Affiliations

First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan. sugimken@hama-med.ac.jp.Centre for Gastroenterology and Inflammatory Bowel Disease Research, Hamamatsu South Hospital, Hamamatsu, 430-0846, Japan.Centre for Gastroenterology and Inflammatory Bowel Disease Research, Hamamatsu South Hospital, Hamamatsu, 430-0846, Japan.Centre for Gastroenterology and Inflammatory Bowel Disease Research, Hamamatsu South Hospital, Hamamatsu, 430-0846, Japan.Centre for Gastroenterology and Inflammatory Bowel Disease Research, Hamamatsu South Hospital, Hamamatsu, 430-0846, Japan.Orthopedics Unit, Hamamatsu South Hospital, Hamamatsu, 430-0846, Japan.Centre for Gastroenterology and Inflammatory Bowel Disease Research, Hamamatsu South Hospital, Hamamatsu, 430-0846, Japan.First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.Inflammatory Bowel Disease Centre, Yokkaichi Hazu Medical Centre, Mie, 510-0016, Japan.Centre for Gastroenterology and Inflammatory Bowel Disease Research, Hamamatsu South Hospital, Hamamatsu, 430-0846, Japan.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

26254083

Citation

Sugimoto, Ken, et al. "An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated With Infliximab Therapy in Patients With Crohn's Disease." Digestive Diseases and Sciences, vol. 61, no. 1, 2016, pp. 99-106.
Sugimoto K, Ikeya K, Iida T, et al. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease. Dig Dis Sci. 2016;61(1):99-106.
Sugimoto, K., Ikeya, K., Iida, T., Kawasaki, S., Arai, O., Umehara, K., ... Hanai, H. (2016). An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease. Digestive Diseases and Sciences, 61(1), pp. 99-106. doi:10.1007/s10620-015-3838-y.
Sugimoto K, et al. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated With Infliximab Therapy in Patients With Crohn's Disease. Dig Dis Sci. 2016;61(1):99-106. PubMed PMID: 26254083.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease. AU - Sugimoto,Ken, AU - Ikeya,Kentaro, AU - Iida,Takayuki, AU - Kawasaki,Shinsuke, AU - Arai,Osamu, AU - Umehara,Keita, AU - Watanabe,Fumitoshi, AU - Tani,Shinya, AU - Oishi,Shinji, AU - Osawa,Satoshi, AU - Yamamoto,Takayuki, AU - Hanai,Hiroyuki, Y1 - 2015/08/08/ PY - 2015/04/07/received PY - 2015/07/30/accepted PY - 2015/8/9/entrez PY - 2015/8/9/pubmed PY - 2016/5/11/medline KW - Bone mineral density KW - Bone resorption KW - Inflammatory bowel disease KW - Infliximab KW - Osteoporosis SP - 99 EP - 106 JF - Digestive diseases and sciences JO - Dig. Dis. Sci. VL - 61 IS - 1 N2 - BACKGROUND: Osteopenia and osteoporosis are considered to be extra-intestinal manifestations of inflammatory bowel disease (IBD). Anti-tumor necrosis factor (TNF)-α biologics have been introduced as novel medications for an active IBD. However, it is still not well documented whether anti-TNF-α affects the frequency of bone loss or abnormality of bone mineral markers among patients with IBD. AIMS: This study was to investigate the biochemical basis of low bone mineral density (BMD) and increased turnover in IBD during infliximab (IFX) therapy. METHODS: Forty patients with Crohn's disease (CD), 80 patients with ulcerative colitis (UC), and 65 age- and gender-matched controls were included. BMD was measured with dual-energy X-ray absorptiometry, and vitamins K and D were measured as serum undercarboxylated osteocalcin (ucOC) and 1,25-(OH)2D, respectively. Bone formation and resorption were based on measuring bone-specific alkaline phosphatase (BAP) and serum N-terminal telopeptide of type I collagen (NTx), respectively. RESULTS: Significantly lower BMD was found in patients with UC and CD as compared to controls (P < 0.05). BAP, 1,25-(OH)2D, ucOC, and NTx were significantly higher in CD patients, but not in UC patients as compared to controls (P < 0.05). Further, serum NTx level was significantly higher in CD patients who were receiving IFX as compared to CD patients who were not receiving IFX (P < 0.01). CONCLUSIONS: A lower BMD and higher bone metabolism markers were found in CD patients as compared to controls or UC patients. A significant increased serum level of NTx, a biochemical marker of increased bone resorption, was observed in CD patients during IFX therapy. SN - 1573-2568 UR - https://www.unboundmedicine.com/medline/citation/26254083/An_Increased_Serum_N_Terminal_Telopeptide_of_Type_I_Collagen_a_Biochemical_Marker_of_Increased_Bone_Resorption_Is_Associated_with_Infliximab_Therapy_in_Patients_with_Crohn's_Disease_ L2 - https://doi.org/10.1007/s10620-015-3838-y DB - PRIME DP - Unbound Medicine ER -